{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:49:01Z","timestamp":1793760541753,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005326","name":"Yale University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019823","name":"University of Maryland, Baltimore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["DB-2020C2-20306"],"award-info":[{"award-number":["DB-2020C2-20306"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008510","name":"University of Maryland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eprac.2026.01.012","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:37:01Z","timestamp":1770050221000},"page":"916-926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial"],"prefix":"10.1016","volume":"32","author":[{"given":"Rozalina G.","family":"McCoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya Sindhu","family":"Swarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Polley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy M.","family":"Mickelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeph","family":"Herrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.01.012_bib1","article-title":"National Diabetes Statistics","year":"2026","journal-title":"Report"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.012_bib2","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.2337\/dc07-0499","article-title":"Patient perceptions of quality of life with diabetes-related complications and treatments","volume":"30","author":"Huang","year":"2007","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.012_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4239\/wjd.v8.i4.120","article-title":"Type 2 diabetes and quality of life","volume":"8","author":"Trikkalinou","year":"2017","journal-title":"World J Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.012_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2337\/dci23-0085","article-title":"Economic costs of diabetes in the US in 2022","volume":"47","author":"Parker","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.012_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.fcl.2022.11.004","article-title":"Diabetic foot considerations related to plantar pressures and shear","volume":"28","author":"Martin","year":"2023","journal-title":"Foot Ankle Clinics"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.012_bib6","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.RVW.15.00080","article-title":"Team approach: treatment of diabetic foot ulcer","volume":"4","author":"Pinzur","year":"2016","journal-title":"JBJS Rev"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.012_bib7","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.2337\/dc21-2151","article-title":"Medical costs associated with diabetes complications in Medicare beneficiaries aged 65 years or older with type 2 diabetes","volume":"45","author":"Wang","year":"2022","journal-title":"Diabetes Care"},{"issue":"1 Suppl 1","key":"10.1016\/j.eprac.2026.01.012_bib8","first-page":"S181","article-title":"Section 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.eprac.2026.01.012_bib9","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.3390\/ijms26209977","article-title":"GLP-1 receptor agonists are associated with reduced ascending aorta dilatation in patients with type 2 diabetes: a prospective study","volume":"26","author":"Sardu","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.012_bib10","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.012_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11892-018-1011-7","article-title":"Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA","volume":"18","author":"Khat","year":"2018","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.eprac.2026.01.012_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.freeradbiomed.2024.01.015","article-title":"Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress","volume":"213","author":"Luna-Marco","year":"2024","journal-title":"Free Radic Biol Med"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.012_bib13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.012_bib14","doi-asserted-by":"crossref","first-page":"C1150","DOI":"10.1152\/ajpcell.00569.2025","article-title":"Vascular effects of SGLT2 inhibitors: evidence and mechanisms","volume":"329","author":"G\u00f3es-Santos","year":"2025","journal-title":"Am J Physiol Cell Physiol"},{"issue":"16","key":"10.1016\/j.eprac.2026.01.012_bib15","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.3390\/ijms22168786","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling","volume":"22","author":"Durante","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.eprac.2026.01.012_bib16","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1111\/bph.15850","article-title":"Amelioration of endothelial dysfunction by sodium glucose co-transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection","volume":"179","author":"Li","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.012_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12916-023-02781-2","article-title":"SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes","volume":"21","author":"Marfella","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.eprac.2026.01.012_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.777083","article-title":"Effects of sodium-glucose transporter 2 inhibitors (SGLT2-I) in patients with ischemic heart disease (IHD) treated by coronary artery bypass grafting via MiECC: inflammatory burden, and clinical outcomes at 5 years of follow-up","volume":"12","author":"Sardu","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eprac.2026.01.012_bib19","article-title":"Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment","volume":"54","author":"D\u2019Onofrio","year":"2021","journal-title":"Mol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.012_bib20","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.012_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis","volume":"15","author":"Heyward","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.012_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12933-021-01276-9","article-title":"SGLT2 inhibitors and lower limb complications: an updated meta-analysis","volume":"20","author":"Lin","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.eprac.2026.01.012_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.diabres.2019.05.028","article-title":"Peripheral artery disease and amputations with sodium-glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized controlled trials","volume":"153","author":"Dicembrini","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.012_bib24","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","article-title":"Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals","volume":"106","author":"Lin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.012_bib25","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.3390\/jcm12123958","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with osteomyelitis and other lower limb safety outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"Nani","year":"2023","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.012_bib26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.012_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100852","article-title":"Derivation of an annualized claims-based major adverse cardiovascular event estimator in type 2 diabetes","volume":"3","author":"McCoy","year":"2024","journal-title":"JACC Adv"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.012_bib29","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.012_bib30","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.eprac.2026.01.012_bib31","author":"Polley"},{"issue":"19","key":"10.1016\/j.eprac.2026.01.012_bib32","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.012_bib33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology"},{"key":"10.1016\/j.eprac.2026.01.012_bib34","series-title":"Design and Analysis of Clinical Trials with Time-to-Event Endpoints: Chapman and Hall\/CRC","first-page":"455","article-title":"Application of time-to-event methods in the assessment of safety in clinical trials","author":"Moore","year":"2009"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.012_bib35","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"17","key":"10.1016\/j.eprac.2026.01.012_bib36","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/sim.7297","article-title":"Causal inference in survival analysis using pseudo-observations","volume":"36","author":"Andersen","year":"2017","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.012_bib37","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/sim.9681","article-title":"A comparison of different methods to adjust survival curves for confounders","volume":"42","author":"Denz","year":"2023","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.012_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jama.2012.96867","article-title":"Prespecified falsification end points: can they validate true observational associations?","volume":"309","author":"Prasad","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.012_bib39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.eprac.2026.01.012_bib40","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.012_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1545","article-title":"Liraglutide for lower limb perfusion in people with type 2 diabetes and peripheral artery disease: the STARDUST Randomized Clinical Trial","volume":"7","author":"Caruso","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10489","key":"10.1016\/j.eprac.2026.01.012_bib42","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.012_bib43","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12933-023-01897-2","article-title":"The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study","volume":"22","author":"Werkman","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.012_bib44","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.012_bib45","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2337\/dc17-2210","article-title":"Limb- and person-level risk factors for lower-limb amputation in the Prospective Seattle Diabetic Foot Study","volume":"41","author":"Boyko","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.012_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.23079","article-title":"Reassessing sulfonylurea safety in modern diabetes care","volume":"8","author":"Ratzki-Leewing","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.012_bib47","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.amjmed.2016.10.016","article-title":"Dipeptidyl peptidase-4 inhibitors, peripheral arterial disease, and lower extremity amputation risk in diabetic patients","volume":"130","author":"Chang","year":"2017","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.012_bib48","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1210\/en.2012-1855","article-title":"Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice","volume":"154","author":"Ervinna","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.eprac.2026.01.012_bib49","article-title":"Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes","volume":"2012","author":"Marfella","year":"2012","journal-title":"J Diabetes Res"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.012_bib50","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.2024.27402","article-title":"Age and sex differences in efficacy of treatments for type 2 diabetes: a network meta-analysis","volume":"333","author":"Hanlon","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.012_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dsx.2020.02.012","article-title":"Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26000297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26000297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:26:59Z","timestamp":1781018819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26000297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1530891X26000297"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.012","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}